ESMOAsia24,gyncsm

Mashup Score: 7

Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer - 19 hour(s) ago

First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.

Source: www.onclive.com

Categories: General Medicine News, Oncologists1

Tweet Tweets with this article
- OncLive
  
  First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer. @myESMO #ESMOAsia24 #gyncsm https://t.co/tDnhPUNc7O